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WHAT IS THE VITAL 90™ DAYS AND WHAT IS IMPORTANT ABOUT IT FROM AN 
ECONOMIC PERSPECTIVE? 
 
The Vital 90™ Days begins approximately 60 days prior to calving and continues 
through the first 30 days of lactation.  During this time, dairy cows experience a series of 
biological and physiological transitions that are usually accompanied by large changes 
in feed intake, dramatic shifts in hormonal profiles, and major fluxes in hepatic demands 
and function.  The resulting negative energy and negative protein balance as well as 
immune suppression often lead to a multitude of metabolic and infectious problems 
including, but not limited to, retained fetal membranes, ketosis, metritis, displaced 
abomasum and mastitis among others.   
 
Cows that experience one or more metabolic or infectious challenges during the 
Vital 90 Days usually experience higher culling and mortality risks.  The reason for the 
higher risk being associated with this periparturient time is multi-fold.  First, due to a 
large decline in feed intake and the hepatic challenge of increased demand for 
gluconeogenesis, cows are more likely to experience metabolic stress in addition to 
infectious challenge.  Second, a significant proportion of cows that experience an 
adverse health issue actually suffer more than one such event increasing the negative 
impact on performance and increasing the culling risk.  Finally, cows that experience 
negative health consequences in early lactation often have carryover effects that impact 
future milk production, reproductive performance, and even future disease risk (Duffield 
et al., 2009; Overton et al., 2008; Santos et al., 2013; Wilson et al., 2004).  As a 
consequence, the short term culling and mortality risk is higher and there is carryover 
impact on future culling risk. 
 
In a similar manner, disease that occurs during The Vital 90 Days is also associated 
with significant milk production losses.  As in the case of culling, milk production losses 
can be measured in terms of immediate impact and in long term impact.  Certain 
diseases such as metritis (with or without retained fetal membranes) and mastitis that 
occur during the immediate post parturient period are often associated with potentially 
large levels of acute milk loss, but these disease events are also associated with longer 
term milk loss either via negative impacts to the lactation curve that are never fully 
recovered or via long term damage to milk secretory cells.  Also, early lactation disease 
such as mastitis is expected to have a greater negative impact on milk production than 
a similar case that occurs later in lactation due to the lactational time at risk.   
 
 
One of the challenges to understanding/estimating the economic impact of disease 
consequences during The Vital 90 Days is the apparent association between diseases.  
As shown in Figure 1, the appearance of one disease challenge is often associated with 
another downstream disease issue (Duffield et al., 2009; Godden et al., 2006; Huzzey 
et al., 2007; Kimura et al., 2002; Loeffler et al., 1999).  For example, cows with 
hyperketonemia (BHBA > 1200 μmol/L) have a higher risk of experiencing a left 
displaced abomasum (LDA), but cows with hyperketonemia in week one postpartum 
have a 6.1X higher risk of experiencing an early lactation LDA as compared to cows 
developing hyperketonemia later (Duffield et al., 2009; McArt et al., 2012).  This is not to 
say that one disease or issue causes another, but rather that there are often 
associations that exist such that when one condition is observed, there is a higher 
likelihood of seeing other related conditions.  In general, cows that experience greater 
immune suppression during the periparturient period are more likely to experience 
retained fetal membranes, metritis, and mastitis; while cows that experience more 
severe negative energy balance are more likely to experience ketosis, displaced 
abomasum, and ovarian dysfunction. 
 
 
Figure 1. Demonstrated and tentative associations between various periparturient 
challenges in dairy cattle. 
 
As a consequence of the multitude of negative impacts of metabolic and infectious 
challenges that occur during the Vital 90 Days, dairy producers and influencers typically 
spend considerable time, money and effort attempting to mitigate the negative impacts 
and consequences of these challenges.  However, despite the high level of financial 
and management investment, few have carefully considered the full magnitude of cost 
incurred by each cow that calves.  Elanco Knowledge Solutions, an analytics team 
within Elanco Animal Health, has developed a new tool to estimate and demonstrate the 
various costs of The Vital 90 Days at the farm level, and to present a new industry 
metric for evaluating transition dairy cow performance, The Vital 90 Days Cost per 
Calving.   
WHAT IS THE ECONOMICS ASSESSMENT TOOL AND WHAT DOES IT DO? 
 
The Economic Assessment Tool is part accounting tool and part economic model.  It 
does not suggest or predict management needs but instead, tabulates all of the various 
costs currently being incurred during The Vital 90 Days other than routine feed costs or 
costs associated with milking during early lactation.  The total cost estimate that is 
calculated by the Economic Assessment Tool is called The Vital 90 Days Cost per 
Calving. 
 
This new metric, The Vital 90 Days Cost per Calving, is comprised of two major 
types of cost.  The first cost for consideration is called the Investment Cost of the Vital 
90 Days and is comprised of all of the vaccinations, therapeutics, nutraceuticals, feed 
additives, and management time and effort used by the dairy and its staff to mitigate 
health risks and to help increase the likelihood of a successful lactation.  The tool allows 
each consultant to input the farm-specific protocols for each individual herd under 
consideration instead of relying on industry-wide estimates, and these inputs are 
stratified into first calving and second or greater calving to reflect potential management 
differences between animals calving for the first time and those returning to lactation.  
As mentioned previously, feed additives are considered in the Investment Costs but the 
base ration cost for each group is not considered. 
 
The second source of costs in The Vital 90 Days is the Consequence Cost.  Despite 
typical preventive efforts, 45-60% of cows typically experience one or more transition-
related disorders (Ribeiro et al., 2013; Santos et al., 2010).  Consequence Cost of 
disease refers to the total impact of disease occurring during this time and is subdivided 
into Direct Disease Costs and Indirect Disease Costs.   
 
Direct Disease Costs include most of the commonly recognized costs associated 
with the impact of disease including diagnostics and therapeutics for clinical cases 
treated, the value of milk that must be discarded during treatment and any required 
withdrawal period, veterinary services, on-farm labor, and death losses that are directly 
associated with specific periparturient disease issues.  Some people may refer to Direct 
Disease Costs as explicit costs since these often seem more tangible and typically 
occur at or very near to the time of disease diagnosis. 
 
Indirect Disease Costs, however, are usually more implicit in nature and often 
represent the “lost opportunity cost” of disease.  The contributors to Indirect Disease 
Costs include any predicted future milk production losses, future culling losses, on-
going diagnostic or monitoring costs, future reproductive losses, and in many cases, 
other diseases that are attributable to the initial disease in question. By summing the 
Direct Disease Costs and the Indirect Disease Costs, the total Consequence Cost is 
determined.  
 
When attempting to calculate the impact (and therefore, the cost) of a specific 
disease on the risk of other downstream diseases, the attributable risk and attributable 
cases must be estimated.  Attributable risk is an epidemiological term that describes the 
difference in disease risk between an exposed population and an unexposed 
population.  In order to calculate the attributable risk, the relative risk (RR) for the 
exposed population as compared to the non-exposed population should be adapted 
from the veterinary literature.  For example, if a herd has a recorded incidence of 40% 
hyperketonemia in early lactation and cows with hyperketonemia have a RR of 8 for 
LDA, then cows with hyperketonemia are 8 times more likely to develop an LDA as 
compared to their non-affected herd mates.  If the underlying risk of LDA for the herd as 
a whole is 3%, the risk of LDA in unaffected cows is ~0.8% and in hyperketonemic 
cows, the risk is ~6.3%.  Consequently, the attributable risk of LDA given 
hyperketonemia is ~5.5%.  Thus, ~88% of the total LDA cases in the herd can be 
attributed to hyperketonemia.  The remaining 12% of the total cases (0.8% incidence in 
the “normal” cows) is found in cows that never experienced primary, early lactation 
hyperketonemia and these cases occurred due to other unexplained reasons. 
 
In the estimation of the Indirect Disease Cost of a specific disease, extreme care 
must be taken to avoid double or triple counting of costs.  In the Economic Assessment 
Tool, two disease cost estimates are given for common transition issues that occur very 
early in lactation and that are linked to other costly outcomes further downstream such 
as clinical hypocalcemia, retained fetal membranes, hyperketonemia, and metritis.  
First, the Component Cost of a disease is reported.  This cost estimate includes those 
Direct and Indirect Disease Costs that are directly attributable to the disease in question 
without consideration of further downstream impacts on other diseases.  By summing all 
of the disease costs not attributable to other diseases, the Component Cost can be 
estimated with minimal risk of double counting disease costs.   
 
Second, the Total Cost of a disease is also reported and this cost estimate includes 
the Component Cost and any additional Direct and Indirect Disease Costs incurred as 
the result of development of other disease issues that are predicted to result as a 
consequence of having the original issue in question.  If the Total Cost of each disease 
reported were added together, a greatly inflated disease cost estimate would be 
created.  Hence, the Total Cost of a disease is only applicable when discussing the 
potential impact of a product or management change on one very specific disease 
without regard to its carry over impact on any other disease. 
 
For example, in the case of hyperketonemia, there is a strong association between 
the presence of elevated ketones in the blood in the early post parturient time period 
and a multitude of adverse health events including, but not limited to, an increased risk 
of culling, death, metritis, displaced abomasa, and future reproductive challenges.  If the 
Total Cost of hyperketonemia was added to the Total Cost of metritis and the Total Cost 
of displaced abomasa, we would grossly overestimate the cost of hyperketonemia and 
the predicted number of cases of metritis and displaced abomasums would greatly 
exceed the herd’s actual number of cases.  However, if we add the component costs of 
each disease, the grand total will more accurately reflect the total impact on the herd.   
 
 
The Economic Assessment Tool adds the total investment cost of the far off, close 
up, and maternity/fresh cows to the total consequence cost (direct and indirect disease 
costs) and reports The Vital 90 Days Cost per Calving by parity.  To correctly tabulate 
all of the Investment and Consequence Costs, a number of inputs must be made 
carefully and correctly.  These inputs consist of the following sections: 
 
1. General herd parameters - The first set of inputs involves whole farm inputs such as 
milk price, labor cost, replacement heifer cost, how waste milk is utilized, culling risk, 
etc.  These inputs serve as the basis for the calculation of many other inputs and 
outputs such as the value of marginal milk and the cost of discarded milk during 
treatment. 
 
2. Preventive protocols - In the Economic Assessment Tool, there is a detailed section 
for customizing each of the routine preventive protocols that occur during the far off, 
close up and calving/fresh periods.  Expected costs, based on currently available 
market prices, are already embedded in the tool but can and should be customized 
for each herd. 
 
3. Disease incidence - In order to correctly tabulate disease costs, the current 
incidence of the various common transition disorders must be input by parity group.  
Unfortunately, many dairies struggle with this area.  Occasionally, herds may record 
disease issues in paper form but fail to enter the information in the computerized on-
farm record system.  Unfortunately, a far more common problem is simply a failure 
to utilize consistent disease definitions along with a failure to consistently record the 
occurrence of disease.  Without proper disease information, the Economic 
Assessment Tool will vastly underestimate The Vital 90 Days Cost per Calving. 
 
4. Treatment protocols - Each herd should have a standardized approach to treatment 
of common transition disorders such as milk fever, ketosis, metritis, mastitis, etc.  
The Economic Assessment Tool has a very detailed data input section that 
facilitates input and customization of the standard treatment protocols for each 
disease issue by parity group.  As with the preventive protocol section, most of the 
commonly used pharmaceutical agents are already present in the tool but may be 
customized in terms of dose, duration, withdrawal and cost in order to more carefully 
and accurately reflect the farm’s current protocols. 
 
When attempting to understand any biological or economic system, the results and 
conclusions reached from analysis are greatly influenced by the accuracy and 
completeness of the inputs and other contributing factors.  Similarly, the utility of the 
Economic Assessment Tool will not be optimized and its full value not realized if the 
inputs in the tool are incomplete or inaccurate.  Hence, careful consideration of the 
herd’s current general parameters, precise description of its preventive and treatment 
protocols, and accurate calculation of true disease incidence is critical.  During 
development and early field use of this tool, the single largest bottleneck to 
capitalization of the value of the Economic Assessment Tool is the inconsistencies or 
total failure to correctly and consistently define and record disease occurrence on 
dairies.  When disease information is not captured, the tool will generate an estimate of 
cost that is lower than reality.  For more information on the topic of disease recording, 
please see the companion paper in these proceedings titled “Disease Records for 
Impactful Decisions During The Vital 90TM Days”. 
 
If inputs have been carefully and accurately made into the Economic Assessment 
Tool, the output will represent the estimated cost of transitioning a cow through the Vital 
90™ Days and will allow the user to now ask pertinent management questions such as 
1) “What is the estimated economic impact of adding input X in the Vital 90 Day 
period?”; 2)“If the incidence of disease Y can be reduced by 30%, how does this impact 
my herd?”; 3) “Given the current level of inputs and disease incidence in my herd, what 
are the biggest opportunities to improve my profitability?”; 4) “How does a change in 
replacement heifer cost or market cow value impact the Cost per Calving?”   
 
Dairy managers and consultants need better decision making tools.  Owners and 
managers are asked to consider using new or improved products on a routine basis.  
However, identifying the cost/benefit or return on investment for these opportunities can 
be difficult. One approach to these types of decisions is to assess the overall investment 
strategy and disease consequence costs of a proposed change. The Economic 
Assessment Tool is a new means to help answer these questions and to help better 
understand the total investment and consequence costs associated with freshening a 
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